OS9
OS9 (OS9 endoplasmic reticulum lectin, also known as OS-9 and ERLEC2) is a lectin of the endoplasmic reticulum lumen. It acts in the HRD1 complex, where it supports ER quality control and ER-associated degradation of misfolded glycoproteins. Browse Assay Genie's current range of OS9 research reagents below, or read on for the biology behind the target.
OS9 is the lectin component of the HRD1 complex, which functions in endoplasmic reticulum (ER) quality control and ER-associated degradation (ERAD). The protein specifically recognises and binds improperly folded glycoproteins as well as hyperglycosylated proteins. It retains them in the ER, passes them to the ubiquitination machinery and promotes their degradation. Possible targets include TRPV4 and hyperglycosylated HSP90B1.
The OS9 protein belongs to the OS-9 family and is assigned by HGNC to the MRH domain containing gene group. UniProt places it in the lumen of the endoplasmic reticulum, consistent with its role in surveying newly folded glycoproteins. The OS9 gene has orthologues named Os9 in both mouse and rat. Alternative transcriptional splice variants encoding different isoforms have been characterised.
The name comes from the gene's original description as osteosarcoma amplified 9; the NCBI Gene summary notes that the protein is highly expressed in osteosarcomas. HGNC also lists the previous name endoplasmic reticulum lectin and the alias ERLEC2. OS9 binds hypoxia-inducible factor 1 (HIF-1), a key regulator of the hypoxic response and angiogenesis, and promotes the degradation of one of its subunits. This links a protein-quality-control factor to oxygen-sensing biology.
OS9 recognises misfolded and hyperglycosylated glycoproteins in the ER lumen and retains them, making it a central factor for studying glycoprotein quality control.
As the lectin component of the HRD1 complex, OS9 passes substrates to the ubiquitination machinery and promotes their degradation.
OS9 binds HIF-1 and promotes degradation of one of its subunits, connecting it to the hypoxic response and angiogenesis.
The gene was named for its amplification and high expression in osteosarcomas, making OS9 a point of interest in tumour biology.
OS9 is the lectin component of the HRD1 complex in ER quality control and ER-associated degradation. It binds improperly folded and hyperglycosylated glycoproteins, retains them in the ER and hands them to the ubiquitination machinery for degradation. Possible targets include TRPV4 and hyperglycosylated HSP90B1.
OS9 is also written OS-9 or ERLEC2, and UniProt lists it as Protein OS-9. HGNC records the previous names osteosarcoma amplified 9 and endoplasmic reticulum lectin. Alternative splice variants encoding different isoforms have been described for the OS9 gene.
Mouse and rat both carry an orthologue named Os9, so rodent models can be used to study it; check the datasheet of any product for its validated reactivity. OS9 is highly expressed in osteosarcomas and binds HIF-1, promoting degradation of one of its subunits.
Other targets with similar names, including oxysterol-binding proteins, osteoclast-related receptors and bone-associated proteins, with products at Assay Genie.
Gene and protein annotations from HGNC, NCBI Gene and UniProt Q13438; product specifications from Assay Genie datasheets.